Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas
暂无分享,去创建一个
[1] H. Ohmatsu,et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. , 2008, Lung cancer.
[2] H. Umezu,et al. Absence of gene mutations in KIT-positive thymic epithelial tumors. , 2008, Lung cancer.
[3] J. Blay,et al. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. , 2008, European journal of cancer.
[4] M. Ross,et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma , 2008, British Journal of Cancer.
[5] C. Yiannoutsos,et al. Imatinib for the treatment of thymic carcinoma , 2008 .
[6] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[7] Charles R. Thomas,et al. Thymic carcinoma: state of the art review. , 2004, International journal of radiation oncology, biology, physics.
[8] A. Marx,et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. , 2004, The New England journal of medicine.
[9] C. Pan,et al. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas , 2004, The Journal of pathology.
[10] O. Cummings,et al. Tyrosine kinase receptor expression in thymomas , 2004, Journal of Cancer Research and Clinical Oncology.
[11] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Huhn,et al. Malignant thymoma: current status of classification and multimodality treatment , 2003, Annals of Hematology.
[13] O. S. Nielsen,et al. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.
[14] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[15] P. Møller,et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients , 2000, The Journal of pathology.
[16] K. Franssila,et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.